Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
GENEVA, Switzerland, January 16 /PRNewswire-FirstCall/ — Merck Serono (virt-x: SEO and NYSE: SRA) announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety [...]
Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
First Trial Assessing Therapeutic Benefit of Two Different Dosage Regimens
of Disease Modifying Therapy in People With First Clinical Symptoms
Suggesting Multiple Sclerosis
GENEVA, Switzerland, December 12 /PRNewswire-FirstCall/ — Serono (virt-x: SEO and NYSE: SRA) announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of [...]